A study found that when a protein-based COVID-19 vaccination was administered as a booster after two doses of an earlier shot from Sinopharm, it elicited a better antibody response against the Omicron version than a third dosage of the original.
Concerns over the efficiency of Sinopharm’s BBIBP-CorV shot, one of the two primary COVID-19 vaccines marketed by China, against the Omicron form prompted the study, which was released on Tuesday but had not been peer reviewed.
A previous investigation found that a BBIBP-CorV booster had worse neutralisation against Omicron than an older coronavirus strain from Wuhan, central China.
Post Your Comments